Advertisement

Berberis aristata DC. (Berberidaceae)

(Syns.: B. bussmul K. Koch ex Miq.; B. coccinea K. Koch; B. elegans K. Koch; B. gracilis Lindl.; B. macrophylla K. Koch; B. umbellata Lindl.)
  • Shahid AkbarEmail author
Chapter
  • 1 Downloads

Abstract

A deciduous evergreen shrub found in temperate and subtropical regions of Asia, Africa, Europe and North and South Americas. It is useful as antipyretic, antimicrobial, hepatoprotective, antihyperglycemic, anticancer, antioxidant, and antilipidemic agent. Bark and stem are tonic, diaphoretic, stomachic, antiperiodic, and gentle aperients, and used in malarial fevers, diarrhea, dyspepsia, dysentery, ague, during convalescence from fevers and acute diseases; the root is purgative. The extract and its formulations have also been used in the treatment of diarrhea, hemorrhoids, gynecological disorders, HIV-AIDS, osteoporosis, diabetes, wound healing, eye and ear infections, jaundice, skin diseases, enlargement of spleen, leprosy, rheumatism, morning/evening sickness, and snakebite. The plant mainly contains isoquinoline alkaloids; major alkaloids identified are berberine, berberrubine, jatrorrhizine, ketoberberine, palmatine, dihydropalmatine, berbamine and pakistanamine. Aqueous-alcoholic root extract significantly lowered FBG in diabetic rats, without causing hypoglycemia, increased glucokinase and G-6-PD activities, and decreased activity of glucose-6-phosphatase. Hydroalcoholic bark extract produced significant anti-inflammatory and antigranuloma effects with significant reduction in proinflammatory markers. A pilot study of a combination product of B. aristata extract and Silybum marianum extract to twenty-six Italian type-2 diabetic patients with suboptimal glycemic control, showed significant reduction in HbA1c, basal insulin, TC, LDL-C, and TGs, after 90-days of treatment. A comparative study of the standardized extract of B. aristata with the fixed combination containing the same standardized extract of B. aristata plus standardized extract of S. marianum showed similar improved fasting glucose, TC, LDL-C, TGs, and liver enzyme levels in both groups, except the HbA1c values were reduced to a greater extent by the fixed combination. Addition of the combination to statin regimen was effective in reducing doses of statins by half in dyslipidemic patients who could not tolerate high doses of statins, without affecting the lipid profile.

Keywords

Amber baarees Begrannter sauerdorn Chitra Darhalad Darchoba Dãruharidrã Indian barberry Lofiyun Rasaut Zarishk 

References

  1. 1.
    Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol. 2001;53:763–8.CrossRefGoogle Scholar
  2. 2.
    Anonymous. Berberine. Altern Med Rev. 2000;5:175–7.Google Scholar
  3. 3.
    Bajpai V, Singh A, Arya KR, Srivastava M, Kumar B. Rapid screening for the adulterants of Berberis aristata using direct analysis in real-time mass spectrometry and principal component analysis for discrimination. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2015;32:799–807.CrossRefGoogle Scholar
  4. 4.
    Chatuphonprasert W, Nemoto N, Sakuma T, Jarukamjorn K. Modulations of cytochrome P450 expression in diabetic mice by berberine. Chem Biol Interact. 2012;196:23–9.CrossRefGoogle Scholar
  5. 5.
    Derosa G, Bonaventura A, Bianchi L, et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther. 2013;13:1495–506.CrossRefGoogle Scholar
  6. 6.
    Derosa G, Bonaventura A, Bianchi L, et al. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents. 2013;27:717–28.PubMedGoogle Scholar
  7. 7.
    Derosa G, D’Angelo A, Maffioli P. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. Clin Nutr. 2016;35:1091–5.CrossRefGoogle Scholar
  8. 8.
    Derosa G, Romano D, D’Angelo A, Maffioli P. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis. 2015;239:87–92.CrossRefGoogle Scholar
  9. 9.
    Derosa G, Romano D, D’Angelo A, Maffioli P. Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine. 2015;22:231–7.CrossRefGoogle Scholar
  10. 10.
    Di Pierro F, Bellone I, Rapacioli G, Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes. 2015;8:89–96.CrossRefGoogle Scholar
  11. 11.
    Di Pierro F, Putignano P, Villanova N, et al. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013;5:167–74.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Di Pierro F, Villanova N, Agostini F, et al. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes. 2012;5:213–7.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Ghosh AK, Bhattacharyya FK, Ghosh DK. Leishmania donovani: amastigote inhibition and mode of action of berberine. Exp Parasitol. 1985;60:404–13.CrossRefGoogle Scholar
  14. 14.
    Gilani AH, Janbaz KH, Aziz N, et al. Possible mechanism of selective inotropic activity of the n-butanolic fraction from Berberis aristata fruit. Gen Pharmacol. 1999;33:407–14.CrossRefGoogle Scholar
  15. 15.
    Gupta SK, Agarwal R, Srivastava S, et al. The anti-inflammatory effects of Curcuma longa and Berberis aristata in endotoxin-induced uveitis in rabbits. Invest Ophthalmol Vis Sci. 2008;49:4036–40.CrossRefGoogle Scholar
  16. 16.
    Janbaz KH, Gilani AH. Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents. Fitoterapia. 2000;71:25–33.CrossRefGoogle Scholar
  17. 17.
    Joshi PV, Shirkhedkar AA, Prakash K, Maheshwari VL. Antidiarrheal activity, chemical and toxicity profile of Berberis aristata. Pharm Biol. 2011;49:94–100.CrossRefGoogle Scholar
  18. 18.
    Kulkarni SK, Dhir A. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol. 2008;589:163–72.CrossRefGoogle Scholar
  19. 19.
    Kulkarni SK, Dhir A. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur J Pharmacol. 2007;569:77–83.CrossRefGoogle Scholar
  20. 20.
    Kumar R, Gupta YK, Singh S. Anti-inflammatory and antigranuloma activity of Berberis aristata DC. in experimental models of inflammation. Indian J Pharmacol. 2016;48:155–61.Google Scholar
  21. 21.
    Pai KS, Srilatha P, Suryakant K, et al. Anticancer activity of Berberis aristata in Ehrlich ascites carcinoma-bearing mice: a preliminary study. Pharm Biol. 2012;50:270–7.CrossRefGoogle Scholar
  22. 22.
    Potdar D, Hirwani RR, Dhulap S. Phytochemical and pharmacological applications of Berberis aristata. Fitoterapia. 2012;83:817–30.CrossRefGoogle Scholar
  23. 23.
    Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Inf Immun. 1982;35:471–5.CrossRefGoogle Scholar
  24. 24.
    Sharma R, Goyal N, Singla M, Sharma VL. Berberis aristata ameliorates testicular toxicity induced by combination of first-line tuberculosis drugs (rifampicin + isoniazid + pyrazinamide) in normal Wistar rats. J Diet Suppl. 2018;28:1–14.Google Scholar
  25. 25.
    Singh J, Kakkar P. Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol. 2009;123:22–6.CrossRefGoogle Scholar
  26. 26.
    Singh M, Srivastava S, Rawat AK. Antimicrobial activities of Indian Berberis species. Fitoterapia. 2007;78:574–6.CrossRefGoogle Scholar
  27. 27.
    Soffar SA, Metwali DM, Abdel-Aziz SS, et al. Evaluation of the effect of a plant alkaloid (berberine derived from Berberis aristata) on Trichomonas vaginalis in vitro. J Egypt Soc Parasitol. 2001;31:893–904.PubMedGoogle Scholar
  28. 28.
    Srivastava S, Rawat AK. Quality evaluation of ayurvedic crude drug daruharidra, its allied species, and commercial samples from herbal drug markets of India. Evid Based Complement Alter Med. 2013;2013:472973.Google Scholar
  29. 29.
    Thakur P, Chawla R, Goel R, et al. Augmenting the potency of third-line antibiotics with Berberis aristata: in vitro synergistic activity against carbapenem-resistant Escherichia coli. J Glob Antimicrob Resist. 2016;6:10–6.CrossRefGoogle Scholar
  30. 30.
    Thakur P, Chawla R, Narula A, et al. In vitro bactericidal activity of Berberis aristate extract against clinical isolates of carbapenem-resistant Escherichia coli. J Complement Integr Med. 2016;13:229–37.CrossRefGoogle Scholar
  31. 31.
    Thakur P, Chawla R, Narula A, Sharma RK. Protective effect of Berberis aristata against peritonitis induced by carbapenem-resistant Escherichia coli in a mammalian model. J Glob Antimicrob Resist. 2017;9:21–9.CrossRefGoogle Scholar
  32. 32.
    Yogesh HS, Chandrashekhar VM, Katti HR, et al. Antiosteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol. 2011;134:334–8.CrossRefGoogle Scholar
  33. 33.
    Zaidi SF, Muhammad JS, Shahryar S, et al. Anti-inflammatory and cytoprotective effects of selected Pakistani medicinal plants in Helicobacter pylori-infected gastric epithelial cells. J Ethnopharmacol. 2012;141:403–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.StocktonUSA

Personalised recommendations